Research programme: polyribitol phosphate antibody therapeutics - Amorfix Life Sciences

Drug Profile

Research programme: polyribitol phosphate antibody therapeutics - Amorfix Life Sciences

Alternative Names: AMF-1c-120; Anti-PrP antibodies - Amorfix; DSE3 ab120; DSE3 ab120/urease

Latest Information Update: 18 Dec 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amorfix Life Sciences
  • Developer Helix BioPharma; ProMIS Neurosciences
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Polyribitol phosphate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Ovarian cancer

Most Recent Events

  • 08 Aug 2014 Suspended - Preclinical for Ovarian cancer in Canada (Parenteral)
  • 09 Apr 2013 Pharmacodynamics data from a preclinical study in Ovarian cancer released by Amorfix
  • 18 Jul 2012 Research programme is available for licensing as of 30 Apr 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top